Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
AstraZeneca
Boehringer Ingelheim
Moodys
Chubb
Fuji
Teva
Johnson and Johnson
Deloitte
Merck

Generated: January 23, 2018

DrugPatentWatch Database Preview

DOXYCYCLINE HYCLATE - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for doxycycline hyclate and what is the scope of doxycycline hyclate patent protection?

Doxycycline hyclate
is the generic ingredient in fourteen branded drugs marketed by Pliva, Mayne Pharma Intl, Warner Chilcott, Medicis, Aqua Pharms, Teva, Actavis Labs Fl Inc, Amneal Pharms, Chartwell Life Sci, Halsey, Heather, Hikma Intl Pharms, Interpharm, Mutual Pharm, Mylan, Par Pharm, Pvt Form, Ranbaxy, Sun Pharm Industries, Superpharm, Watson Labs, Pfizer, Fresenius Kabi Usa, Rachelle, Mylan Labs Ltd, West-ward Pharms Int, Zydus Pharms Usa Inc, Tolmar, Mayne Pharma, Actavis Elizabeth, Heritage Pharms Inc, Impax Labs Inc, Mylan Pharms Inc, Prinston Inc, Aqua Pharms Llc, Amneal Pharms Co, Caribe Holdings, Epic Pharma Llc, Ivax Sub Teva Pharms, Lannett, Larken Labs, Lupin Ltd, Mayne Pharma Inc, Novel Labs Inc, Vintage Pharms, Collagenex, and Galderma Labs Lp, and is included in seventy-one NDAs. There are five patents protecting this compound and seven Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Doxycycline hyclate has two patent family members in two countries.

There are twenty-seven drug master file entries for doxycycline hyclate. Ninety-five suppliers are listed for this compound.
Summary for DOXYCYCLINE HYCLATE
Pharmacology for DOXYCYCLINE HYCLATE
Ingredient-typeTetracyclines
Drug ClassTetracycline-class Drug

US Patents and Regulatory Information for DOXYCYCLINE HYCLATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pvt Form DOXYCYCLINE HYCLATE doxycycline hyclate CAPSULE;ORAL 062631-002 Jul 24, 1986 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Zydus Pharms Usa Inc DOXYCYCLINE HYCLATE doxycycline hyclate TABLET;ORAL 207773-001 Oct 30, 2017 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mayne Pharma DORYX doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-005 Apr 11, 2013 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Pfizer VIBRAMYCIN doxycycline hyclate CAPSULE;ORAL 050007-002 Approved Prior to Jan 1, 1982 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mayne Pharma DORYX doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-002 May 6, 2005 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Mayne Pharma DORYX doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-003 Jun 20, 2008 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Mayne Pharma DORYX MPC doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-007 May 20, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Mayne Pharma DORYX MPC doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-007 May 20, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Mayne Pharma DORYX doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-003 Jun 20, 2008 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Mayne Pharma DORYX doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-005 Apr 11, 2013 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for DOXYCYCLINE HYCLATE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,016,151,395 ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
McKesson
Fuji
Julphar
Fish and Richardson
Accenture
US Army
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot